Fresenius Medical Care Corporation (FMS) Receives News Impact Rating of 0.10
News coverage about Fresenius Medical Care Corporation (NYSE:FMS) has been trending somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fresenius Medical Care Corporation earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.2923627462076 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Saudi Arabia Medical Devices Market to grow at a CAGR Over ~9.5% During -2017-2023 (emailwire.com)
- ETFs with exposure to Fresenius Medical Care AG & Co. KGaA : November 10, 2017 (finance.yahoo.com)
- Fresenius Medical Care Corporation (FMS) vs. Air Methods Corp (AIRM) Head-To-Head Survey (americanbankingnews.com)
- Fresenius Medical Care Corporation to Post FY2017 Earnings of $2.30 Per Share, SunTrust Banks Forecasts (FMS) (americanbankingnews.com)
Several equities analysts recently commented on FMS shares. BidaskClub downgraded shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Royal Bank Of Canada reiterated a “neutral” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, August 1st. DZ Bank AG reiterated a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Monday, August 7th. Finally, Zacks Investment Research downgraded shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $48.50.
Shares of Fresenius Medical Care Corporation (NYSE FMS) opened at $48.42 on Monday. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22. The firm has a market cap of $29,813.26, a P/E ratio of 21.71, a PEG ratio of 2.18 and a beta of 0.45. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.22 and a quick ratio of 0.98.
Fresenius Medical Care Corporation Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.